Piramal Pharma Ltd. has seen a decline in shareholding across all categories: Promoters down 0.09% YoY and QoQ, Institutions down 0.52% YoY but a slight increase of 0.24% QoQ, and Public down 0.41% YoY and 0.01% QoQ, indicating a lack of confidence.

In contrast, sector averages for Promoters and Institutions show no change, suggesting that while the sector remains stable, Piramal Pharma is experiencing internal selling pressure.

The best performer in the sector, Sudarshan, saw a significant institutional increase of 18.88%, highlighting that there are opportunities within the sector that are attracting smart money, further emphasizing Piramal's underperformance.